Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIO-RAD LABORATORIES, INC.

(BIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bio Rad Laboratories : Citigroup Adjusts Price Target on Bio-Rad Laboratories to $750 From $675, Maintains Buy Rating

02/12/2021 | 11:00am EST


ę MT Newswires 2021
All news about BIO-RAD LABORATORIES, INC.
11/29BIO-RAD LABORATORIES, INC. : Other Events (form 8-K)
AQ
11/18BIO-RAD LABORATORIES, INC. : Entry into a Material Definitive Agreement, Creation of a Dir..
AQ
11/18Bio-Rad Laboratories, Inc. Enters into Amendment No.1 to Credit Agreement
CI
10/29BIO-RAD LABORATORIES, INC. Management's Discussion and Analysis of Financial Condition..
AQ
10/29Tranche Update on Bio-Rad Laboratories, Inc.'s Equity Buyback Plan announced on Novembe..
CI
10/28Bio-Rad Laboratories Q3 Earnings, Sales Gains Beat Expectations; Issues FY21 Guidance -..
MT
10/28Bio-Rad Reports Third-Quarter 2021 Financial Results - Form 8-K
PU
10/28BIO-RAD : Q3 Earnings Snapshot
AQ
10/28Bio-Rad Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
10/28Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q3 EPS $3.71, vs. Street Est of $2.48
MT
More news
Analyst Recommendations on BIO-RAD LABORATORIES, INC.
More recommendations
Financials (USD)
Sales 2021 2 896 M - -
Net income 2021 541 M - -
Net cash 2021 1 174 M - -
P/E ratio 2021 42,1x
Yield 2021 -
Capitalization 22 578 M 22 578 M -
EV / Sales 2021 7,39x
EV / Sales 2022 7,23x
Nbr of Employees 8 000
Free-Float 71,2%
Chart BIO-RAD LABORATORIES, INC.
Duration : Period :
Bio-Rad Laboratories, Inc. Technical Analysis Chart | BIO | US0905722072 | MarketScreener
Technical analysis trends BIO-RAD LABORATORIES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 755,56 $
Average target price 812,50 $
Spread / Average Target 7,54%
EPS Revisions
Managers and Directors
Norman D. Schwartz Chairman, President & Chief Executive Officer
Ilan Daskal Chief Financial Officer & Executive Vice President
Andrew J. Last Chief Operating Officer & Executive Vice President
Jeffrey L. Edwards Independent Director
Gregory K. Hinckley Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIO-RAD LABORATORIES, INC.29.21%22 578
ABBOTT LABORATORIES15.75%222 397
MEDTRONIC PLC-8.91%143 497
BECTON, DICKINSON AND COMPANY-5.23%67 353
HOYA CORPORATION27.30%58 627
DEXCOM, INC.48.31%54 527